



ASH 2025 Tip Sheet: Sylvester Researchers Contribute to More Than 35 Oral Presentations at ASH Annual Meeting

MIAMI, FLORIDA - Research findings from Sylvester Comprehensive Cancer Center and the University of Miami Miller School of Medicine will be presented at ASH 2025, the 67th-annual meeting and exposition of the American Society of Hematology in Orlando, Florida, Dec. 6-9.

In addition, Dr. Mikkael Sekeres, chief of the Division of Hematology, will chair a special session titled Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults.

For information on session dates and times, or to arrange interviews under embargo, please email sandy.van@miami.edu.

Oral Presentations (with links to full abstracts)

1. **Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma**

Dr. Jay Spiegel is the presenting author and all other authors are with Sylvester or the University of Miami.

2. **A phase 2 trial of abbreviated fixed-duration (Default 4 Cycles) linvoseltamab immuno-consolidation to deepen responses post newly diagnosed multiple myeloma combination therapy for minimal residual disease positivity (the IMMUNOPLANT Study)**

Dr. Dickran Kazandjian is the presenting author and all authors are with Sylvester or the University of Miami.

3. **A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study**

Dr. Benjamin Diamond is the presenting author and all authors are with the Myeloma Institute at Sylvester.

4. **Clinical translation of single cell measurable residual disease (scMRD) assay in real world Acute Myeloid Leukemia (AML) patients**

Dr. Katarina Micin is the presenting author.

5. **A Phase 2 trial of AI-BEL (AZT/Interferon- α plus Belinostat) for HTLV-1 related adult T-cell leukemia-lymphoma: Final safety and efficacy Results**

Dr. Juan Carlos Ramos is the presenting author.

6. **Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia**

Dr. Justin Watts is the presenting author.

7. **Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study**

Dr. Antonio Jimenez Jimenez is the last co-author.

8. **CAR-T efficacy in large B-cell lymphoma is shaped by neoantigen-driven epitope spreading and limited by HLA loss and genomic instability**

Multiple Sylvester physicians are co-authors.

9. **3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma**

Dr. Craig Moskowitz is a co-author.

10. **First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctDNA analysis from dose escalation**

Dr. Craig Moskowitz is a co-author.

11. **Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study**

Drs. Ellen Madarang and Justin Watts are co-authors.

12. **The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission**

Dr. Antonio Jimenez-Jimenez is a co-author.

13. **Safety and efficacy results from a phase 1b study of R289, a dual irak 1/4 inhibitor, in patients with Relapsed/Refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS).**

Dr. Mikkael Sekeres is a co-author.

14. **Correlation between treatment-emergent cytopenias and clinical response with imetelstat (IME) in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS): Analysis from the imerge Trial**

Dr. Mikkael Sekeres is a co-author.

15. **Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial**

Dr. Namrata Chandhok is a co-author.

16. **Genomics define neoplastic transformation in multiple myeloma precursor conditions**

Several Sylvester physicians are co-authors.

17. Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma

Dr. Juan Alderuccio is a co-author.

18. Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Dr. Izidore S. Lossos is a co-author.

19. Survival difference among patients with large B-cell lymphoma (LBCL) based on first-line clinical trial participation: A multi-institutional analysis of 8 academic institutions in the lymphoma epidemiology of outcomes (LEO) cohort

Dr. Izidore S. Lossos is a co-author.

20. Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma

Dr. Izidore S. Lossos is a co-author.

21. Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Dr. Lazaros Lekakis is a co-author.

22. Spen loss drives extra-follicular diffuse large B cell lymphoma with female-specific lethality and TLR pathway therapeutic vulnerabilities

Dr. Kenneth Hoehn is a co-author.

23. Loss of p53 enhances LMO2 induced transdifferentiation of B-cells to T-cell acute lymphoblastic leukemia

Dr. Izidore S. Lossos is presenting author and Shlomzion Aumann and Daniel Bilbao, PhD, are co-authors.

24. Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Dr. Dickran Kazandjian is a co-author.

25. Novel immune gene expression signature risk-stratifies Mantle Cell Lymphoma outcomes independent of TP53 status

Drs. Jennifer Chapman and Izidore S. Lossos are co-authors.

26. Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Drs. Mikkael Sekeres and Namrata Chandhok are co-authors.

27. Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Dr. Alvaro Alencar is a co-author.

28. Fircabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Dr. Jay Spiegel is a co-author.

29. CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation

Dr. Damian Green is a co-author.

30. Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Dr. James Hoffman is a co-author.

31. Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Dr. Justin Watts is a co-author.

32. Preliminary anti-leukemia activity from a phase 1 study of clin-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Dr. Namrata Chandhok is a co-author.

33. Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus

Dr. Sangeetha Venugopal is a co-author.

34. Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

Dr. Alvaro Alencar is a co-author.

35. Safety and efficacy of bromodomain and extra-terminal protein inhibitor INCB057643 monotherapy in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: A phase 1 study

Dr. Justin Watts is a co-author.

36. Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study

Dr. Juan Alderuccio is the presenting author and Dr. Izidore S. Lossos is a co-author.

###

MEDIA CONTACT

Sandy Van
sandy.van@miami.edu